eligibility_summary
Adults 18–75 with ECOG 0–1, ≥3‑mo survival, unresectable/metastatic solid tumors that are CLDN18.2+, with measurable disease and adequate marrow/organ function. Exclude: recent/ongoing anticancer therapy/surgery, HER2+, unresolved AEs, ≥G2 neuropathy, study drug/antibody allergy, CNS/meningeal mets, dysphagia, other malignancy, autoimmune disease/recent immunosuppression, lung disease, ≥G3 effusion, active infection, HIV/HBV/HCV, transplant, severe cardio/cerebrovascular disease, recent GI perforation/fistula or bleed, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: SHR-A1904 (anti-CLDN18.2 antibody–drug conjugate, ADC) combined with adebrelimab (anti–PD-L1 monoclonal antibody), with or without CAPOX (capecitabine + oxaliplatin). Mechanisms: SHR-A1904 binds CLDN18.2 on tumor cells, is internalized, and releases a cytotoxic payload to selectively kill CLDN18.2-positive cells, adebrelimab blocks PD-L1 to restore PD-1–mediated T-cell antitumor activity, capecitabine (prodrug of 5-FU) inhibits thymidylate synthase and DNA synthesis, oxaliplatin forms DNA crosslinks leading to apoptosis. Targets/pathways: CLDN18.2 on epithelial tumor cells, PD-1/PD-L1 immune checkpoint on T cells/tumor microenvironment, nucleotide synthesis and DNA damage pathways in rapidly dividing tumor cells.